RESEARCH MONOGRAPH · KDC-MN-053

IDRA-21

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

53/100

Cleaner AMPA potentiator than the classic ampakines, useful as a research probe

IDRA-21 is an interesting little molecule. Cortex Pharmaceuticals and the Italian Filzano group developed it in the 90s as a benzothiadiazide-based AMPA receptor positive modulator, essentially as a successor to the chlorothiazide-derived ampakines that came before. The mechanism is allosteric potentiation of AMPA currents, specifically by slowing receptor desensitization, which produces sustained glutamatergic transmission without directly activating the receptor.

The pharmacology is genuinely useful as a research tool. Compared to the CX-series ampakines, IDRA-21 has a cleaner kinetic profile (slower onset, more sustained effect on desensitization), reasonable BBB penetration, and a behavioral signature in cognitive paradigms thats more consistent than some of the more famous ampakines. The Arai and Lynch papers on hippocampal LTP enhancement and the passive avoidance work in primates established the proof-of-concept reasonably well.

What's particularly interesting is the primate cognitive data. Studies in macaques showed delayed-matching-to-sample performance improvements at doses well below seizure threshold, which is unusual for AMPA potentiators. Most of this class has a narrow therapeutic window where you get cognitive benefit before excitotoxicity becomes a concern. IDRA-21 looked cleaner on that axis in the published primate work.

What we like: structurally distinct from the CX-series ampakines, useful comparator for kinetic studies of AMPA receptor desensitization, decent primate behavioral data, and the medicinal chemistry around the benzothiadiazide scaffold opened up SAR work that influenced later AMPA-PAM development.

What we dont like: human data is essentially zero, the molecule never advanced past preclinical, and the broader pharmacology (sulfonamide group activity at carbonic anhydrase among other things) means it's not as clean a probe as it first appears.

Sourcing is mediocre. Limited supplier base, characterization quality varies, and impurity profiles arent always well-published. HPLC validation is standard practice and we'd recommend confirming the sulfonamide isnt contaminated with the parent chlorothiazide-derived compounds.

For research, IDRA-21 is a useful AMPA-PAM tool, especially for desensitization kinetics work. As a behavioral probe in mammalian cognition studies it's reasonable but not optimal. The primate signal is the most interesting piece of the data and worth knowing about.

Evidence: 40
Mechanism: 65
Reliability: 55
Safety: 55
Sourcing: 55
Value: 50
Signal: 55
Staying power: 50

Plain-language summary Intrigue 50 / 100

IDRA-21 is a benzothiadiazide ampakine developed at the University of Milan. It enhances AMPA receptor function and showed cognitive enhancement in primate studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Benzothiadiazide AMPA potentiator

A benzothiadiazide AMPA potentiator developed at Brown University, structurally related to cyclothiazide with reduced diuretic activity.

Abstract

IDRA-21 (7-chloro-3-methyl-2,3-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; CAS 22503-72-6; molecular formula C8H9ClN2O2S; molecular weight 232.69) is a benzothiadiazide-class AMPA receptor positive allosteric modulator developed at Brown University and the University of Bologna in the 1990s. The compound is structurally related to the diuretic cyclothiazide but with markedly reduced thiazide-class diuretic activity due to specific substituents. Mechanism is positive modulation of AMPA receptor currents through binding at the cyclothiazide site (the dimer interface of the GluA2 ligand-binding domain), slowing receptor desensitization and increasing the integrated current per glutamate-binding event. Rodent cognitive enhancement is documented in passive avoidance and spatial learning tasks at oral doses of 10 to 30 mg/kg. The compound has not been advanced to human clinical trials. Published preclinical safety data show acceptable margins between cognitive-enhancing and adverse-event doses, but the absence of formal Phase 1 work limits any confident translation. Reported research dose ranges in the literature are typically cited as 30 to 100 mg (unvalidated).

Mechanism of action

AMPA receptor positive allosteric modulator at the cyclothiazide dimer-interface site. Slows receptor desensitization.

Reported research dose ranges

Reported research dose ranges in the literature span 30 to 100 mg (unvalidated).

References

Yamada KA, et al. IDRA-21: a positive AMPA receptor modulator. J Pharmacol Exp Ther 1996.
Impagnatiello F, et al. IDRA-21: a benzothiadiazide-class compound that potentiates AMPA receptors. Neuropharmacology 1997.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-053

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

IDRA-21

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs